Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers

Terminated

Conditions: Dry Eye

Interventions: Device: Contact Lens Wear
Other: Non-Contact Lens Wear

First Posted Date: 2011-03-17

Last Posted Date: 2020-01-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 25

Registration Number: NCT01317030

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

A Study to Evaluate a New Silicone Hydrogel Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Investigational Lens
Device: Air Optix Aqua lens

First Posted Date: 2011-03-07

Last Posted Date: 2014-11-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 66

Registration Number: NCT01309893

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Evaluation of a New Silicone Hydrogel Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Air Optix Aqua
Device: Test lens

First Posted Date: 2011-03-07

Last Posted Date: 2015-02-23

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 66

Registration Number: NCT01309880

Locations: 🇺🇸
Bausch & Lomb, Incorporated, Rochester, New York, United States

Evaluation of the Feasibility a New Silicone Hydrogel Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Investigational lens
Device: Air Optix Aqua lens

First Posted Date: 2011-03-07

Last Posted Date: 2020-10-22

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 66

Registration Number: NCT01309906

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: PureVision Toric Lens
Device: Investigational Toric Lens

First Posted Date: 2011-03-07

Last Posted Date: 2020-10-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 302

Registration Number: NCT01309867

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Product Feasibility of a New Silicone Hydrogel Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Investigational Lens
Device: Acuvue Oasys Lens
Device: Air Optix Aqua Lens

First Posted Date: 2011-03-04

Last Posted Date: 2014-04-29

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 144

Registration Number: NCT01309100

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

Evaluation of Two Daily Disposable Contact Lenses.

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: Experimental- Soflens
Device: Marketed - Soflens

First Posted Date: 2011-02-21

Last Posted Date: 2020-10-06

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 441

Registration Number: NCT01300065

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Phase 3

Terminated

Conditions: Inflammation
Pain
Cataract

Interventions: Drug: Mapracorat
Drug: Vehicle

First Posted Date: 2011-02-18

Last Posted Date: 2020-09-03

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 177

Registration Number: NCT01298752

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Phase 2

Completed

Conditions: Conjunctivitis, Allergic

Interventions: Drug: Mapracorat
Drug: Vehicle

First Posted Date: 2011-02-03

Last Posted Date: 2020-09-04

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 236

Registration Number: NCT01289431

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Bepotastine Besilate Nasal Spray 4% Twice a day
Drug: Bepotastine Besilate Nasal Spray 2% Twice a day
Drug: Bepotastine Besilate Nasal Spray 3% Twice a day
Drug: Placebo Nasal Spray

First Posted Date: 2011-01-14

Last Posted Date: 2020-10-05

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 601

Registration Number: NCT01277341

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy